ProBio Launches Advanced Facility In Hopewell, NJ

ProBio Inc., a contract development and manufacturing organization (CDMO) based in New Jersey, has broadened its plasmid DNA and viral vector manufacturing capabilities with the launch of a new facility in Hopewell, New Jersey. This facility will act as the central hub for ProBio's North American operations, significantly bolstering the company's ability to support cell and gene therapy manufacturing across the continent.

Covering approximately 128,000 square feet, the Hopewell facility includes office, laboratory, and manufacturing spaces equipped with cutting-edge technology and equipment for process development and current good manufacturing practice (cGMP) production. This includes the manufacturing of plasmid DNA and viral vectors such as adeno-associated virus, lentivirus, and retrovirus.

Li Chen, CEO of ProBio Inc., "We are proud to expand our capabilities to manufacture life-changing biologic drugs to the growing cell and gene therapy industry. Our dedicated, talented team and state-of-the-art manufacturing facility here in Hopewell, N.J., will help expedite bringing these therapies to patients. This expansion underscores our commitment to accelerating the delivery of advanced therapies to patients."

This site facilitates technology transfer, method and analytical development, and process development, while also supporting the manufacturing of drug substances and drug products for both clinical and commercial-grade plasmid DNA and viral vector-based therapies. All operations adhere to stringent quality control and quality assurance standards. To further enhance the company's capabilities and strengthen its position in the biotech sector, the facility's cGMP suites will be renovated to produce plasmid DNA and viral vectors for phase-appropriate programs.

 Patrick Liu, Chairman of ProBio, further said, "The Hopewell facility exemplifies our mission to bring innovative therapies from concept to reality. By enhancing our capabilities, we not only support the rapid development of novel treatments but also ensure that these therapies reach patients more efficiently and effectively."